A real-world retrospective single-centre study of the cost-effectiveness and long-term outcomes of pegylated interferon for chronic hepatitis B.

Stephen E ConglyAhsan SyedSarah Haylock-JacobsHeidi IsraelsonJacqueline PintoSarah WilliamsSamuel S LeeCarla S Coffin

Published in: Canadian liver journal (2023)

PEG-IFN remains a potential treatment for CHB although there is a significant intolerance/failure rate. Using PEG-IFN based on patient preference is reasonable and optimal patient selection may improve treatment cost-effectiveness.

Keyphrases

dendritic cells
immune response
case report
drug delivery
climate change